About
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportDallas and The Woodlands, Texas (September 30, 2015) – PCCI, a non-profit research and development corporation specializing in real-time predictive healthcare analytics, and The US Oncology Network, one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care, have entered into an agreement to develop two oncology solutions that will run on PCCI’s Pieces™ software platform.
“Our hope is that this work will lead to improvement of quality of life for lung and pancreatic cancer patients and their families as well as have a measurable impact on improving care and avoiding hospitalizations,” states Ruben Amarasingham, MD, MBA, president and CEO of PCCI.
The oncology solutions, architected by PCCI data scientists, will be developed for two cancer types: Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) and Stage IV Pancreatic Cancer, chosen because of their high relative rates of hospitalization. PCCI developers in collaboration with The US Oncology Network will use the data to construct software to help physicians make better, faster and more informed decisions on a patient’s treatment.
The ultimate goal is to identify high-risk individuals and assess the utility of interventions that decrease the frequency of undesired outcomes such as emergency department visits, hospitalizations and readmissions. Physicians at high volume sites within Texas Oncology, a practice in The US Oncology Network, will review the results, and program success will be measured by comparing the data output against a validation cohort.
“We are very excited to work with PCCI to build and test these models,” said Marcus Neubauer, MD, medical director of Oncology Services for McKesson Specialty Health and The US Oncology Network. “Cancer treatment is associated with side effects, and some patients get much sicker than others. We hope to better assess a patient’s risk for illness and deterioration prior to initiating treatment. This way, cancer patients can receive treatment and feel better and be more productive along the way.”
This unique collaboration also represents a platform expansion into oncology for PCCI, and a multi-party collaborative that includes data contributions from other hospital organizations. Says Amarasingham, “with program success, PCCI hopes to help further The US Oncology Network as the leader in the movement towards patient-centered and value-based care in oncology.”
About The US Oncology Network
The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.
About PCCI
PCCI is a high tech research and development company and innovation think tank focused on healthcare. The Pieces™ software interprets EMR data in real-time, transforming them into useful intervention warning tools that assist physicians and hospitals on complex clinical decisions in every fields of medicine. Headquartered in Dallas, Texas, PCCI’s vision is to deploy predictive and surveillance solutions around the world that make healthcare safer, simpler, and less stressful. For more information, visit www.pccipieces.org.